Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire
Oliver Rumle Hovmand, Dea Siggaard Stenbæk, M. Madsen, Patrick M. Fisher
Journal of Psychopharmacology August 13, 2024 DOI: 10.1177/02698811241269669 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Validation study Peer reviewed |
|---|---|
| Sample size | 597 |
| Population | Healthy volunteers receiving psilocybin in a laboratory setting and recreative users of psychedelics |
| Intervention | Psilocybin |
| Topics | Psilocybin Altered states of consciousness |
| Keywords | Danish Altered state Consciousness Recreation Clinical psychology Hallucinogen |
| Citations | 9 |
| Key points | The Danish 5D-ASC is a valid tool for measuring altered states of consciousness, with the 11-subscale structure showing better fit than the five-dimensional solution and total scores correlating positively with psilocybin dose. |
Abstract
Background: Psychedelic substances reliably induce marked altered states of consciousness (ASC), which may be important for lasting effects and clinical outcomes of psychedelic intervention. Several instruments are available to measure the acute psychedelic experience, of which the Five Dimensional Altered States of Consciousness Questionnaire (5D-ASC) is commonly used. The questionnaire can be scored and analyzed as having five dimensions or 11 subscales, but the two have not been evaluated with comparable factor analysis methods.
Methods: The Danish translation of the 5D-ASC was completed by one sample of healthy volunteers receiving psilocybin in a laboratory setting ( N = 47) and one sample of recreative users5D-ASC of psychedelics ( N = 550), who reported retrospectively through an online survey based on their most recent experience with psilocybin. We calculated internal consistency measures of Cronbach’s alpha and McDonald’s omega, conducted a confirmatory factor analysis of the previously suggested factor structures, and tested for possible associations between the 5D-ASC total scores and dose, setting, and intention. For the 11 subscales, we reported omega-sem (composite reliability) using the parameters of the fitted confirmatory factor analyses model.
Results: Confirmatory factor analysis showed that the 11 subscales had a good fit to data and showed a better fit compared to the originally proposed five-dimensional solution and good internal consistencies. We further found that the 5D-ASC total scores correlated positively with the dose in the recreative sample. We found no correlations between 5D-ASC total scores and intention or setting.
Discussion: We find the Danish 5D-ASC to be a valid tool for measuring ASC among Danish-speaking individuals.
Citations in the library
Cited by 8
- Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study Journal of Psychopharmacology February 28, 2025
- OAV and 5D-ASC for Brazilian Portuguese: A validation and adaptation study. Journal of Psychopharmacology June 28, 2025
- The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research. Journal of Psychopharmacology December 26, 2025
- Setting the Stage for the Inner Journey: Unraveling the Interplay of Contextual Factors and the Intensity of Psychedelic-Induced Ego Dissolution. Journal of Psychoactive Drugs February 13, 2025
- Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study Research Square August 23, 2024
and 3 more in the library
Cites 36
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
and 31 more in the library